Workflow
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
10x Genomics10x Genomics(US:TXG) Prnewswireยท2025-09-09 13:00

Core Insights - CLISEQ Ltd. has announced a collaboration with 10x Genomics and the Weizmann Institute to launch the PERIBLOOD clinical trial, which aims to evaluate single cell RNA sequencing from blood as a non-invasive method for diagnosing blood disorders [1][2][3] - The trial will enroll over 1,500 participants globally and compare single cell profiles from peripheral blood with traditional bone marrow aspiration results to assess the viability of this new diagnostic approach [1][2][3] Group 1: Clinical Trial Details - The PERIBLOOD trial is a three-year study sponsored by the Weizmann Institute, with plans to enroll participants from North America, Europe, Asia, Latin America, and Israel [1] - Participants will include individuals with low and high blood counts, as well as healthy volunteers, to evaluate the effectiveness of the new diagnostic method for Myelodysplastic Syndromes (MDS) and other hematological disorders [1][2] Group 2: Technology and Methodology - The trial utilizes a novel technology developed by Professors Liran Shlush and Amos Tanay, which has shown the ability to accurately diagnose MDS from peripheral blood [2][5] - 10x Genomics' Chromium GEM-X Single Cell technology will be employed to analyze thousands of individual cells in each blood sample, generating detailed molecular profiles that may reveal insights missed by traditional testing methods [3][4] Group 3: Implications and Future Directions - If successful, the study could lead to a significant shift in how blood disorders are diagnosed, making the process less invasive and more accessible [4][5] - The findings from this trial may inform future diagnostic product development in hematology, enhancing patient experience and clinical decision-making [4][5]